120 related articles for article (PubMed ID: 24913092)
1. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Luizon MR; Palei AC; Sandrim VC; Amaral LM; Machado JS; Lacchini R; Cavalli RC; Duarte G; Tanus-Santos JE
Pharmacogenomics J; 2014 Dec; 14(6):535-41. PubMed ID: 24913092
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Lacchini R; Duarte G; Tanus-Santos JE
Pharmacogenomics J; 2012 Dec; 12(6):489-98. PubMed ID: 21769110
[TBL] [Abstract][Full Text] [Related]
3. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Duarte G; Tanus-Santos JE
Exp Mol Pathol; 2012 Apr; 92(2):217-21. PubMed ID: 22327101
[TBL] [Abstract][Full Text] [Related]
4. Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Luizon MR; Palei ACT; Belo VA; Amaral LM; Lacchini R; Duarte G; Cavalli RC; Sandrim VC; Tanus-Santos JE
Pharmacogenomics J; 2017 Oct; 17(5):427-434. PubMed ID: 27168100
[TBL] [Abstract][Full Text] [Related]
5. Effects of matrix metalloproteinase (MMP)-2 polymorphisms on responsiveness to antihypertensive therapy of women with hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Lacchini R; Duarte G; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2012 Oct; 111(4):262-7. PubMed ID: 22672240
[TBL] [Abstract][Full Text] [Related]
6. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension.
Sandrim VC; Palei AC; Luizon MR; Izidoro-Toledo TC; Cavalli RC; Tanus-Santos JE
Pharmacogenomics J; 2010 Feb; 10(1):40-5. PubMed ID: 19704415
[TBL] [Abstract][Full Text] [Related]
7. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
8. [Expression of trophoblast invasion related genes mRNA and protein in human placenta in preeclampsia].
Zhang H; Lin QD; Qiao C
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):509-13. PubMed ID: 17083831
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and 2 as potential biomarkers for gestational hypertension.
Ab Hamid J; Mohtarrudin N; Osman M; Andi Asri AA; Wan Hassan WH; Aziz R
Singapore Med J; 2012 Oct; 53(10):681-3. PubMed ID: 23112021
[TBL] [Abstract][Full Text] [Related]
11. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis.
Lorente L; Martín M; Plasencia F; Solé-Violán J; Blanquer J; Labarta L; Díaz C; Borreguero-León JM; Jiménez A; Páramo JA; Orbe J; Rodríguez JA; Salido E
Crit Care; 2013 May; 17(3):R94. PubMed ID: 23706069
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
13. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients.
Demacq C; Vasconcellos VB; Marcaccini AM; Gerlach RF; Machado AA; Tanus-Santos JE
Pharmacogenomics J; 2009 Aug; 9(4):265-73. PubMed ID: 19381161
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.
Onal IK; Altun B; Onal ED; Kirkpantur A; Gul Oz S; Turgan C
Eur J Intern Med; 2009 Jul; 20(4):369-72. PubMed ID: 19524176
[TBL] [Abstract][Full Text] [Related]
15. Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levels.
Marson BP; Lacchini R; Belo V; Mattos SG; da Costa BP; Poli-de-Figueiredo CE; Tanus-Santos JE
Clin Chim Acta; 2012 Dec; 414():46-51. PubMed ID: 23010359
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension.
Palei AC; Sandrim VC; Duarte G; Cavalli RC; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2010 Jun; 411(11-12):874-7. PubMed ID: 20211160
[TBL] [Abstract][Full Text] [Related]
17. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia.
Chiang TY; Yu YL; Lin CW; Tsao SM; Yang SF; Yeh CB
Clin Chim Acta; 2013 Sep; 424():261-6. PubMed ID: 23792071
[TBL] [Abstract][Full Text] [Related]
18. A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury.
Jacob-Ferreira AL; Passos CJ; Gerlach RF; Barbosa F; Tanus-Santos JE
Sci Total Environ; 2010 Sep; 408(19):4085-92. PubMed ID: 20554312
[TBL] [Abstract][Full Text] [Related]
19. Placental production and maternal serum and urine levels of inhibin A and activin A are modified by antihypertensive therapy in hypertensive disorders of pregnancy.
Khalil A; Jauniaux E; Harrington K; Muttukrishna S
Clin Endocrinol (Oxf); 2009 Jun; 70(6):924-31. PubMed ID: 18803676
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
